Drug not effective in preventing bypass vein clogging

November 13, 2005

DALLAS-- A new drug, edifoligide, designed to prevent the clogging of veins used in coronary bypass surgery was no more effective than a placebo, according to the results of a Phase III clinical trial led by researchers at Duke Clinical Research Institute (DCRI).

In a coronary artery bypass procedure, surgeons typically remove portions of the saphenous vein from patients' legs and use them as conduits to reroute blood around a blockage in arteries supplying blood to the heart. The most common reason for subsequent failure of the grafts is the progressive narrowing of the vein, which is largely the result of a process known as neointimal hyperplasia.

Since veins are structurally different from arteries, the increased pressure and stress on the implanted vein causes proliferation of smooth muscle within the vessel. Edifoligide, an E2F transcription factor inhibitor, showed an ability in earlier studies to block this cellular proliferation.

"The results of our Phase III trial showed that the edifoligide was absolutely neutral in all endpoints when compared to placebo," said Duke cardiologist John Alexander, M.D., who presented the results of the trial Nov. 13, 2005, at the annual scientific sessions of the American Heart Association. The results of the trial are also being published early and online by the Journal of the American Medical Association.

"Failure of at least one vein graft is quite common within a year of bypass surgery" Alexander said. "While edifoligide had no effect in preventing neointimal hyperplasia, longer-term follow-up and additional research is needed to determine whether the drug has longer-term beneficial effects and to better understand the mechanisms and consequences of vein graft failure."

In response to shear forces and increased pressures in the vein, cells growth increases in the inner lining of the vein. These cells secrete a variety of proteins known as cytokines that modulate the immune response. These cytokines cause inflammation that intensifies the process of atherosclerosis in the newly formed tissue. The family of E2F transcription factors has been implicated in "turning on" many of the genes responsible for this process.

The drug edifoligide is an oligonucleotide "decoy" or short fragment of DNA, that is structurally similar to the E2F transcription factor binding site, and thereby blocks E2F transcription factor binding and subsequent gene activation. The drug appeared to be promising in animal models and two small clinical trials involving 41 and 200 patients, said the researchers.

The latest randomized, double-blind trial, known as PREVENT-IV, enrolled 3,014 patients at 107 U.S. sites who underwent coronary artery bypass graft procedures involving at least two vein grafts. Half of the patients had their leg veins pressure-treated with the drug for ten minutes prior to implantation, while the veins of control patients were treated in the same way, but with a placebo. The average number of veins grafted was about 2.5 per patient.

The primary endpoint measured by researchers was how many patients had at least one vein graft more than 75 percent blocked more than a year after surgery.

The researchers found that 45.2 percent of patients with treated veins had at least one vein more than 75 percent blocked, compared to 46.3 percent for the control group. In terms of total veins, 28.5 percent of treated veins were more than 75 percent occluded, compared to 29.7 percent in the control group. The differences were not clinically or statistically significant, said the researchers.

There was also no difference between the two groups in terms of clinical events, they said. In the treated group, 7.6 percent of patients experienced death, heart attack or need for another procedure, compared to 9.1 percent for the control group.

The results of the trial were similar to that of PREVENT III, which tested the drug in patients who underwent peripheral artery bypass surgery.

"Given the results we've seen in the latest two large clinical trials (PREVENT III and IV), the earlier promising results with edifoligide were probably due to its small sample size, less complete follow-up, or chance," Alexander said.

The DCRI is currently leading a Phase I/II pilot trial (PREVENT V), which is assessing the effectiveness of edifoligide in preventing neointimal hyperplasia in vascular access grafts in patients undergoing dialysis for kidney failure.

While the results of PREVENT IV were largely negative, Alexander said that researchers gained insights. For example, the process developed to infuse the drug into the vein tissue could be used in other surgical settings where a drug needs to be delivered to a single site instead of systemically.
-end-
The trial was funded by Corgentech, Inc. South San Francisco, developer of the drug and Bristol Myers Squibb, N.Y., who partnered with Corgentech in the development of the drug. Alexander has no financial interests in Corgentech.

Duke University Medical Center

Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.